Form 4: Aprea Therapeutics Executive John P. Hamill Reports Acquisition of Common Stock
SEC Form 4 Filing
John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, Inc., acquired 50 shares of common stock at a price of $2.4638 on October 11, 2024.
Summary
- On October 11, 2024, John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, Inc., acquired 50 shares of common stock.
- The price per share was $2.4638.
- Following the transaction, Hamill directly owns 19,368 shares of Aprea Therapeutics, Inc.
Sentiment
Score: 5
Explanation: This is a neutral event. An executive purchased a small number of shares, which doesn't necessarily indicate strong positive or negative sentiment about the company's future.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when an officer of a publicly traded company buys or sells shares in their own company. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The purchase of shares by a company executive can sometimes be seen as a positive signal to investors, but the impact of this small transaction is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 10/11/2024 | Date of transaction: John P. Hamill acquired 50 shares of Aprea Therapeutics common stock. |
| 10/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.